I-Mab 대차 대조표 상태

재무 상태 기준 확인 4/6

I-Mab 의 총 주주 지분은 $217.9M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $232.7M 및 $14.8M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$184.39m
주식	US$217.88m
총 부채	US$14.80m
총 자산	US$232.68m

최근 재무 상태 업데이트

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Feb 08

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

Recent updates

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

재무 상태 분석

단기부채: IMAB 의 단기 자산 ( $188.2M )이 단기 부채( $11.8M ).

장기 부채: IMAB 의 단기 자산( $188.2M )이 장기 부채( $3.0M ).

부채 대 자본 내역 및 분석

부채 수준: IMAB 부채가 없습니다.

부채 감소: IMAB 는) 부채 대 자기자본 비율이 9.3% 였던 5년 전과 비교하여 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: IMAB 의 현재 여유 현금 흐름을 기준으로 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

예측 현금 활주로: IMAB 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

I-Mab 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

Recent updates

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

Consensus revenue estimates fall by 32%

Price target decreased to US$87.94

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Founder notifies of intention to sell stock

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

Chief Commercial Officer notifies of intention to sell stock